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Background
The CD4-binding site (CD4BS) on HIV-1 gp120 is func-
tionally conserved and structurally invariant, and the
broadly neutralizing antibody b12 exploits this site of vul-
nerability to achieve neutralization. However, most anti-
bodies that target this general epitope cannot effectively
neutralize HIV-1. Why is HIV-1 resistant to neutralization
by these antibodies? Comparison at the atomic level of
gp120 binding to effective and non-effective antibodies
may reveal the answer.
Methods
We solved the crystal structure of gp120 in complex with
one of the non-effective CD4BS antibodies called b13 at
2.5 Å.
Results
Antibody b13 binds gp120 in a very similar manner to
that of antibody b12, with three heavy chain complemen-
tarity-determining regions grabbing onto the CD4-bind-
ing loop of gp120. The contacting surface of antibody b13
on gp120 overlaps significantly with that of b12, and the
approach angle of b13 and b12 differ by only 17 degrees.
However, the binding surface is shifted towards a confor-
mationally variable region on gp120. This shift results in
large conformational changes to the alpha1-helix, the V1/
V2 stem as well as the beta20/beta21 region. Computa-
tional modeling indicates that these antibody-induced
conformational changes are not compatible with trimeric
constraints on the viral spike.
Conclusion
Our results suggest that targeting of the CD4-binding site
by an antibody which slightly misses the precise site of
CD4 attachment results in a cascade of conformational
changes in gp120. These changes are incompatible with
the viral spike, which in turn protects HIV-1 from being
neutralized. Precise targeting is therefore needed. The
structures of both effective and non-effective antibodies in
complex with gp120 therefore define a vulnerable vaccine
target, which is confined by glycan on one side and by
conformationally variable areas on the other.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P66 doi:10.1186/1742-4690-6-S3-P66
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P66
© 2009 Zhou et al; licensee BioMed Central Ltd. 